Australia markets open in 42 minutes

GeoVax Labs, Inc. (GOVX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.0700-0.1900 (-15.08%)
At close: 04:00PM EDT
1.1000 +0.03 (+2.80%)
After hours: 07:17PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.2600
Open1.1800
Bid1.0400 x 1000
Ask1.0700 x 1100
Day's range1.0400 - 1.1900
52-week range0.5500 - 7.5000
Volume2,585,316
Avg. volume9,882,772
Market cap13.426M
Beta (5Y monthly)1.79
PE ratio (TTM)N/A
EPS (TTM)-2.9700
Earnings date09 Aug 2022 - 15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.00
  • GlobeNewswire

    GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development

    Operational Resources Strengthened to Support Company Growth and Development Atlanta, GA, June 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of John W. Sharkey, PhD to serve as Vice President, Business Development. Dr. Sharkey brings over 30 years of experience in the pharmaceutical and medical device industry, with specific expertise

  • GlobeNewswire

    GeoVax to Present at BIO International Convention 2022

    Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine and Immuno-oncology/Gedeptin® Atlanta, GA, June 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present at the BIO International Convention 2022 being held June 13-16 in San Diego. Details of the presentation are as follows: Date: June 15

  • GlobeNewswire

    GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules

    Atlanta, GA, May 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 3,030,304 shares of common stock at a purchase price of $1.65 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at a p